LMP 517
Alternative Names: Fluoroindeno antibody drug complex; Fluoroindenoisoquinolines antibody drug complex; LMP517; LMP517 antibody drug complex; LMP517-ADCLatest Information Update: 28 May 2024
At a glance
- Originator Gibson Oncology; National Cancer Institute (USA)
- Developer Gibson Oncology
- Class Antibodies; Antineoplastics; Drug conjugates; Fluorine compounds; Immunoconjugates; Immunotherapies; Immunotoxins; Indenes; Isoquinolines
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 06 Apr 2020 Preclinical trials in Solid tumours in USA (Parenteral), prior to April 2020 (Gibson Oncology website, April 2020)